Cumberland Pharmaceuticals Inc. · NASDAQ:CPIX
Cumberland Pharmaceuticals — Investor Presentation (October 2026)
25 slides from Cumberland Pharmaceuticals's investor presentation, October 2026
Slide 1: Corporate Presentation
Corporate Presentation Targeting Multiple Diseases with Substantial Market Opportunities Dyscorban® Vasculan® Fibroban® + additional expansion programs DMD cardiomyopathy systemic sclerosis pulmonary fibrosis October 2026
Slide 2: Why Cumberland, Why Now
INVESTMENT THESIS Why Cumberland, Why Now Significant value creation opportunities Attractive, underserved markets Lead DMD program advancing to an NDA, plus multiple Limited or no effective treatment options for addressable Phase 2 programs built on one core molecule patient populations — no approv
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 are made only as of the date of this presentation. Forward-looking statements may be identified by words such as “may,” “will,” “expect,” “plan,
Slide 4: A New Cumberland: Value Unlocked, Focused on Innovation
A DEFINING MOMENT A New Cumberland: Value Unlocked, Focused on Innovation THE STRATEGIC TRANSACTION OUR NEW STRATEGY STRATEGIC TRANSACTION · CLOSED SUMMER 2026 TAG LINE Cumberland Pharmaceuticals Advancing innovative therapies integrated its commercial products and organization with MISSION Advancin
Slide 5: Ifetroban: A De-Risked Molecule with Multiple Commercial Opportunities
THE OPPORTUNITY Ifetroban: A De-Risked Molecule with Multiple Commercial Opportunities Positive Phase 2 DMD Data Well-Established Safety Profile Key FDA Designations Ifetroban improved heart function vs. a declining ~1,400 subjects dosed across ~30 clinical studies, Orphan Drug, Rare Pediatric Disea
Slide 6: A Well-Capitalized Company Focused on Its Rare-Disease Pipeline
COMPANY SNAPSHOT A Well-Capitalized Company Focused on Its Rare-Disease Pipeline ~$100M+ 3 Core ~30 Net Divestiture Proceeds Clinical Programs Ifetroban Studies From sale of commercial assets 3 ifetroban Ph2 + other expansion ~1,400 subjects dosed A Proven Record of FDA Approvals Ifetroban — The Val
Slide 7: Ifetroban: Once-Daily Oral Dosing, With Several Mechanisms of Action
THE MOLECULE Ifetroban: Once-Daily Oral Dosing, With Several Mechanisms of Action What it is How it works Ifetroban is a potent, selective antagonist of the thromboxane receptor (TPr) — expressed • Once-daily oral capsules taken in a fasted state on cardiomyocytes, immune cells, smooth-muscle cells
Slide 8: 1 Molecule, 3 Core Programs — and Expansion Opportunities
PIPELINE 1 Molecule, 3 Core Programs — and Expansion Opportunities Preclinical Phase 1 Phase 2 Phase 3 NDA Ifetroban in DMD Phase 2 complete · Pre-NDA meeting held · NDA planned Dyscorban® · cardiomyopathy Ifetroban in SSc Phase 2a complete · topline reported Vasculan® · systemic sclerosis Ifetroban
Slide 9: Anticipated Milestones Across the Portfolio
CORPORATE NEWS FLOW Anticipated Milestones Across the Portfolio ANTICIPATED MILESTONES → DMD Open-label extension data Initiate rolling NDA submission › (24 & 36 month) › Complete NDA submission › Conference presentation of data Dyscorban® SSc Correlative biomarker studies & OLE cardiac Submit clini
Slide 10: Ifetroban in Duchenne Muscular Dystrophy
LEAD PROGRAM Ifetroban in Duchenne Muscular Dystrophy Addressing cardiomyopathy — the leading cause of death in DMD
Slide 11: DMD Cardiomyopathy: A Progressive, Fatal & Underserved Problem
THE DISEASE DMD Cardiomyopathy: A Progressive, Fatal & Underserved Problem Cardiomyopathy prevalence rises with age The Natural History <10 yrs 17% 10–15 yrs 34% ~3% typical annual LVEF decline in DMD Once heart function declines, it does not recover with existing therapy — making >15–18 yrs 59% ear
Slide 12: Dyscorban: ~15,300 U.S. DMD Patients, No Approved Cardiac Therapy
MARKET OPPORTUNITY — DMD CARDIOMYOPATHY Dyscorban®: ~15,300 U.S. DMD Patients, No Approved Cardiac Therapy ~15,300 300+ >90% 0 U.S. DMD patients New U.S. cases each year Develop cardiomyopathy as adults Approved cardiomyopathy therapies Published estimates: 15,000–17,500 ~1 in 5,000 live male births
Slide 13: How Ifetroban Protects the Heart
MECHANISM OF ACTION How Ifetroban Protects the Heart The problem DMD gene mutation leads to weakened muscle cells resulting in calcium overload in heart cells, oxidative stress, cardiomyocyte death and progressive cardiac fibrosis. The target Calcium overload Ifetroban is a potent, selective antagon
Slide 14: Ifetroban Improved Survival & Cardiac Output in Severe DMD Models
PRECLINICAL FOUNDATION Ifetroban Improved Survival & Cardiac Output in Severe DMD Models ↑ Survival ↑ Output ↓ Vasoconstriction Extended survival in two severe DMD Improved cardiac index and stroke Reduced abnormal coronary mouse models volume vasoconstriction Peer-Reviewed Published in Journal of t
Slide 15: A Randomized, Placebo-Controlled Phase 2 Trial
CLINICAL — FIGHT DMD A Randomized, Placebo-Controlled Phase 2 Trial 41 High-dose ifetroban Open-Label Extension n=18 · 300 mg/day • All participants receive high-dose ifetroban • 21 subjects through 36 months; 16 to 48 months patients with DMD Low-dose ifetroban • ~90 patient-years of ifetroban expo
Slide 16: Ifetroban Improved Heart Function After 12 Months
CLINICAL RESULTS — EFFICACY Ifetroban Improved Heart Function After 12 Months Heart Pumping — Preserved vs. Control Heart Strain Marker — Reduced +5.4% LVEF −54 pg/mL Between-group difference in LVEF at 12 months, high-dose ifetroban vs. placebo- Average reduction in NT-proBNP, a blood marker of hea
Slide 17: A Clear, Dose-Dependent Preservation of Cardiac Function
CLINICAL RESULTS — DOSE RESPONSE A Clear, Dose-Dependent Preservation of Cardiac Function 4 Key Takeaways 2 +1.8 +1.8% High-dose ifetroban improved LVEF over one year CFB LVEF at 12 months (%) 0.0 0 0% Low-dose held function flat -2 -1.5 −3.6% to −4.3% Placebo-plus-natural-history & matched natural-
Slide 18: Blood Biomarkers Support Heart-Muscle Protection
CLINICAL RESULTS — BIOMARKERS Blood Biomarkers Support Heart-Muscle Protection Circulating proteins moved in directions consistent with protection & repair — corroborating the functional (LVEF) results. Markers of Protection & Repair — Increased Markers of Cell Damage — Reduced 2.4× 2.1× ↓ 30% ↓ 50%
Slide 19: A Well-Characterized Safety Profile
CLINICAL RESULTS — SAFETY A Well-Characterized Safety Profile ~1,400 0 ~90 yrs Participants Dosed Drug-Related SAEs Cumulative Exposure across ~30 clinical studies in the FIGHT DMD double-blind period patient-years of ifetroban in DMD participants What we observed Why safety de-risks the platform •
Slide 20: FDA Designations, IP & the Path to NDA
REGULATORY, IP & CATALYSTS FDA Designations, IP & the Path to NDA Orphan Drug Rare Pediatric Disease Fast Track Designation approved Priority Review Voucher eligible Designation granted (Feb 2026) Plus >$1M in FDA Orphan Products Grant funding awarded to support development. Multiple issued patents
Slide 21: Beyond DMD: Expanding the Franchise
PLATFORM EXPANSION Beyond DMD: Expanding the Franchise Two additional Phase 2 programs in high-value fibrotic diseases
Slide 22: Two Additional Phase 2 Programs with the Same Molecule
PIPELINE EXPANSION Two Additional Phase 2 Programs with the Same Molecule Systemic Sclerosis Idiopathic Pulmonary Fibrosis Vasculan® Fibroban® • Debilitating, chronic autoimmune disease — skin thickening & fibrosis of • IPF is the most common progressive fibrosing interstitial lung disease internal
Slide 23: Well-Capitalized Balance Sheet
C A P I T A L I ZA T I O N Well-Capitalized Balance Sheet Recent Commercial Divestiture ~$100M+ Net Divestiture Proceeds ~$100M+ Non-dilutive capital in net proceeds from the sale of the company's commercial products 3 1 Phase 2 Programs Core Molecule • Non-dilutive capital raised at attractive valu
Slide 24: In Summary
SUMMARY In Summary Significant value creation opportunities Compelling clinical trial results to date in DMD Established safety profile Ownership of worldwide commercial rights Solid financial position Expected near-term news flow Cumberland Pharmaceuticals | Nasdaq: CPIX 23
Slide 25: Reimagining Treatment Across Multiple Diseases
Reimagining Treatment Across Multiple Diseases A de-risked, novel molecule — led by DMD and expanding across multi-billion-dollar opportunities Proven Safe Scalable Positive Phase 2 data ~1,400 subjects, dosed across ~30 studies Multiple programs, one core molecule Nasdaq: CPIX · www.cumberlandpharm
Cumberland Pharmaceuticals — Investor Presentation (October 2026) on 6ix